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Herein we report the use of pyridazinediones to functionalise the native solvent accessible interstrand
disulﬁde bonds in trastuzumab with monomethyl auristatin E (MMAE). This method of conjugation
delivers serum stable antibody–drug conjugates (ADCs) with a controlled drug loading of 4. Moreover,
we demonstrate that the MMAE-bearing ADCs are potent, selective and eﬃcacious against cancer cell
lines in both in vitro and in vivo models.Antibody–drug conjugates (ADCs) are a promising class of bio-
therapeutics primarily aimed at cancer treatment. ADCs
combine the cell-killing potency of a toxic drug with the target
selectivity of an antibody towards overexpressed receptors on
cancer cell membranes. Their relevance is demonstrated by two
FDA-approved ADCs already in the market, brentuximab vedo-
tin (Adcetris™) and trastuzumab emtansine (Kadcyla™), and
over 40 ADCs undergoing clinical trials.1,2
The choice of conjugation method to covalently attach a drug
to an antibody has a direct eﬀect on the control over drug loading
and aﬀects several properties of the resulting ADC, such as
potency, selectivity, stability, clearance rate and therapeutic
index.3–5 Lysine conjugation is the method employed to produce
Kadcyla™ but the high abundance of lysines results in a hetero-
geneous distribution of antibody conjugates with diﬀerent drug
loadings and therapeutic indexes.6–8 Maleimide conjugation to
cysteines of an interstrand reduced IgG1 exploits the lower
abundance of solvent accessible disuldes to reduce heteroge-
neity. This is exploited in the synthesis of Adcetris™ by rst
reducing the solvent accessible disuldes in the antibody, fol-
lowed by conjugation to a maleimide-functionalised drug-linker
construct.9 Despite the reduction in heterogeneity, the resulting
ADC is still composed of multiple species with loss of interstrand
disulde bonds and an overall suboptimal performance inLondon, London, WC1H 0AJ, UK. E-mail:
k; Tel: +44 (0)20 7679 2653; +44 (0)20
ndon, UK
ESI) available: Synthetic procedures, 1H
mpounds, additional SDS-PAGE gels,
supplementary results. See DOI:
is work.
hemistry 2017pharmacokinetics and therapeutic index.10–14 The existence of
high drug to antibody ratio (DAR) species has been recognised to
lead to physical instability, faster clearance and lower therapeutic
index, highlighting the need to carefully control drug loading
during ADC synthesis.8,10,11,15 In fact, homogeneity of DAR species
has already been demonstrated to improve therapeutic index.16–18
The linker joining the drug to the conjugation site must be stable
in circulation and enable drug release following internalisation
into the target cell, with the linker stability being recognised
as a major challenge. This is exemplied following the data on
the acyl hydrazone linkers that were employed in Mylotarg™,3,19
and thioether-succinimide conjugates, employing classical mal-
eimides for cysteine conjugation, undergoing retro Michael
(leading to deconjugation and transfer onto thiols such as
albumin20).18,21
New conjugation strategies have been developed to address
these challenges, such as engineered cysteines through site-
directed mutagenesis8,22 and non-natural amino acids for bio-
orthogonal conjugation.13,23,24 These strategies rely on protein
engineering and thus represent a move away from the simple
concept of a chemical strategy for post-translational modica-
tion of a native antibody. We feel that chemical methods that
are employed on native antibody scaﬀolds which reduce
heterogeneity and aﬀord complete drug loading control are
highly desirable for ADC production. Site-selective disulde
bridging with small molecules ts these requirements. We have
developed two classes of molecules used for functional disulde
re-bridging, namely next-generation maleimides (NGMs)25–32
and pyridazinediones (PDs).33–37 Godwin and co-workers have
also pioneered bis-sulfones as reagents for disulde bridging
and ADC synthesis.17,38
Recently, we have shown the use of NGMs for ADC
synthesis,30 and have shown the ADCs to have good selectivityRSC Adv., 2017, 7, 9073–9077 | 9073
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View Article Onlinetowards creating DAR 4 conjugates and to have stability in blood
serum, as well as in vitro potency.26 NGMs require stabilisation
against thiol scavenging conditions by hydrolysing to maleamic
acid conjugates under basic pH.25,26,28 PD-conjugates on the
other hand are stable to hydrolysis, less reactive in thiol scav-
enging conditions and also stable against retro Michael. Thus,
PDs do not require any additional modication beyond conju-
gation to deliver stable ADCs; although (prior to this commu-
nication) they were only shown to be stable in blood plasma
mimicking conditions.37 In addition, PDs have been shown to
be amenable to forming 2-in-1 reagents for both disulde
reduction and stapling to reduce ADC heterogeneity as well as
to be amenable to making controlled DAR 2 ADCs.34 The PDScheme 1 Exempliﬁcation of NGM and PD technology platforms for
insertion into a disulﬁde bond.
Fig. 1 Modiﬁcation of reduced disulﬁde bonds in a IgG1 antibody with: (
structural bonds; (B) NGMs and PDs leading to more homogeneous an
conjugates prepared in this work.
9074 | RSC Adv., 2017, 7, 9073–9077scaﬀold has also been shown to incorporate dual click handles,
which enables controlled modication of each PD bridged
disulde with two distinct agents.37 However, to date, there has
been no in vivo data on PD conjugates and no serum stability or
hydrophobic interaction chromatography (HIC) analysis.
Herein, we demonstrate the synthesis and evaluation of PD-
based ADCs with an industry relevant drug monomethyl auri-
statin E (MMAE). We show that these ADCs are synthesised
almost exclusively as DAR 4 species (by HIC and mass spec),
have stability in blood serum and are selective and potent
against HER-2 expressing tumour cells. Moreover, we demon-
strate for the rst time that both NGM- and PD-based ADC
potency and selectivity translate well into therapeutic eﬃcacy in
an in vivo mouse model. Both ADC formats showed excellent
tumour regression.
Both NGM and PD based ADCs are prepared by a common
and simple method (Scheme 1). The four solvent accessible
disulde bonds in an IgG1 are reduced using tris-2-
carboxyethylphosphine (TCEP), followed by functional re-
bridging with either a NGM or a PD molecule. Conjugation
with NGM is followed by hydrolysis to stabilise the conjugate,
whereas PD conjugates themselves are stable.
We chose trastuzumab as our antibody platform to demon-
strate disuldemodication with PDs. Trastuzumab (Herceptin™)
is a monoclonal IgG1 antibody targeting HER2 and is used for
breast cancer therapy both as antibody alone39 and as the antibody
component of ADC Kadcyla™.40We chose anti-cancer drugMMAE
as a suitable payload for ADC design.9,38,41 Lastly, we chose toA) classical maleimides leading to a heterogeneous mixture and loss of
d retention of structural bonds. (C) NGM-MMAE and PD-MMAE ADC
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinecompare cleavable and non-cleavable linker designs. The cleavable
linker design is the widely used cathepsin B labile valine–citruline
linker.8,9,38,42,43
It has been suggested that MMAE requires release as a free
drug from the antibody linker conjugate to reach anywhere near
its full potency inside the target cell.44 However, our previously
reported NGM-MMAE ADC 1 showed high potency in vitro
despite using a non-cleavable linker.26 Therefore, we chose to
prepare both non-cleavable and cleavable linker versions of PD-
MMAE ADCs (ADCs 3 and 4, Fig. 1), and re-synthesise NGM-
MMAE ADC 1 for further evaluation. We also prepared an
analytical amount of classical maleimide-based ADC 2 (a
common conjugation strategy employed to make ADCs) to
compare its HIC prole against our technology.
The synthesis and characterisation of NGM-MMAE ADC 1
was previously described.26 Synthesis of classical maleimide-
MMAE ADC 2 was adapted from a reported protocol (Fig. 1,
see ESI for details†).9 PD based bridging reagents, with cleav-
able or non-cleavable linkers, were synthesised from a previ-
ously reported PD scaﬀold36 in reasonable yields (see ESI for
details†). ADCs 3 and 4 were obtained by treatment of TCEP-
reduced trastuzumab with the relevant bridging reagent as
illustrated in Scheme 1. To our delight, in line with the best
industry standard, mass spectrometry analysis of the conjugates
conrmed ADCs 3 and 4 to each have a DAR of 4 as the most
predominant species by far (Fig. 2A and B, respectively).Fig. 2 MS data for: (A) PD-MMAE ADC 3, and; (B) PD-MMAE ADC 4. (C)
HIC analysis of PD-MMAE ADC 3. (D) SEC-HPLC analysis data from
stability study of AFC 5. (E) AFC 5 conjugate.
This journal is © The Royal Society of Chemistry 2017Further to this, key HIC analysis of PD-MMAE ADC 3 showed
this conjugate to be synthesised almost exclusively as a DAR 4
species (Fig. 2C). This stands in stark contrast with the typical
mixture of diﬀerent DAR species obtained for classical
maleimide-MMAE conjugate 2 (see ESI for full HIC data†). HIC
analysis of PD-MMAE ADC 4 displays a more complex pattern to
ADC 3; this conjugate appears as a wider peak with a shoulder.
Previous HIC analysis of disulde bridged MMAE ADCs bearing
the valine–citrulline linker in the literature also show a similar
pattern and those results were interpreted by Badescu et al. as
DAR 4 species.38 Furthermore, HIC analysis of NGM-MMAF
ADCs in the literature interpreted these as isomorphs of DAR
4 species.16 Furthermore, we have shown that LCMS analysis of
PD-MMAE 4 to reveal the DAR 4 species almost solely (Fig. 2B);
this represents the best control of loading for such reagents in
the eld, to the best of our knowledge.
Following this, we examined the stability of antibody-PD
conjugates in blood serum. To do this, an alkyne bearing PD
reagent was synthesised (PD-propargylamide, see ESI for
details†), which would simulate the linker properties of the
reagent used for PD-MMAE ADC 3. PD-propargylamide was
conjugated to trastuzumab, and then click functionalised with
AlexaFluor® 488-azide to give antibody-uorophore conjugate
(AFC) 5 (Fig. 2E). The conjugate was incubated in blood serum
over 7 days and compared side-by-side with a classical mal-
eimide counterpart conjugate as control. Whereas the classical
maleimide control displayed signicant transfer of uorescence
from trastuzumab to serum albumin (see ESI for details†), the
PD conjugate showed minimal transfer (Fig. 2D), and is
certainly at the very least comparable to the best reagents in the
eld.
The in vitro potency of all our ADCs was next evaluated
against HER2-positive human breast cancer cell line HCC1954.
The HER2-negative cell line MCF-7 was used as a negative
control. Both cell lines are sensitive to MMAE with IC50 values of
0.2 nM and 0.9 nM for HCC1954 and MCF-7, respectively.
Gratifyingly, the ADCs proved to be highly potent against the
HER2-positive cell line, whilst having potency greater than two
orders of magnitude lower for the HER2-negative MCF-7 (Fig. 3,
top). PD-MMAE ADCs 3 and 4 were found to reduce HCC1954
cell viability with low nM to pM IC50 values. Whilst the eﬀect of
having a cleavable linker made a large diﬀerence for the PD-
conjugates, equi-drug loaded non-cleavable linker NGM ADC
1 showed potency comparable to cleavable linker PD-MMAE
ADC 4 – which tallies with our previous results.26
We then evaluated the in vivo eﬃcacy of our ADCs in
a human breast cancer xenogramodel using the HCC1954 cell
line. The ADCs were dosed at 20 mg kg1 on days 1, 8 and 15,
which is in line with other interchain disulde bridging
ADCs.17,38 Gratifyingly, all ADCs achieved tumour inhibition
soon aer the rst day of therapy (Fig. 3, bottom le). Tumour
inhibition was sustained during and aer dosing, leading to
complete regression 18 days aer start of therapy. No tumour
recurrence was observed during the remainder of the study, up
to day 45, when the study was terminated. Notably, trastuzumab
alone was not eﬃcacious and showed no improvement over the
untreated vehicle. Furthermore, the ADCs were well toleratedRSC Adv., 2017, 7, 9073–9077 | 9075
Fig. 3 In vitro potency of MMAE, Herceptin, and ADCs 1, 3 & 4 on
HCC1954 cells, and MCF-7 cells. Cell viability was plotted against
antibody/MMAE concentration. In vivo eﬃcacy of ADCs 1, 3 and 4
showing relative tumour volume during course of treatment, and
mouse weight during study.
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View Article Onlinewith no signicant change in body weight observed (Fig. 3,
bottom right). As we dosed at a relatively high level, and the
advantages of having such homogenous DAR 4 conjugates are
so well characterised and understood, we were not aiming to see
a signicant diﬀerence in the in vivo potency of PD-ADCs 3–4
and NGM-ADC 1 but rather show that our platforms can be: (i)
successfully employed in an in vivo setting with almost certain
downstream advantages in terms of PK prole, tolerability,
stability, clearance rate and therapeutic index, and (ii) that it is
useful but not essential for the ADCs to have a cleavable linker
in order to make eﬃcacious MMAE-based ADCs.
To conclude, MMAE-bearing PD reagents were synthesised
and conjugated to trastuzumab to prepare novel PD-MMAE
ADCs 3 and 4 with exceptional control towards DAR 4
species with state-of-the-art characterisation. The PD-
modied antibody conjugates were also shown to be stable
in serum and retain binding aﬃnity. The PD-MMAE ADCs 3
and 4, as well as NGM-MMAE ADC 1, were shown to be active
against a HER2-positive human breast cancer cell line in an in
vitro assay in the sub-nM range, and showed excellent eﬃcacy
in a mouse xenograph model with the cleavable linker portion
of the linker shown to not be essential to the activity of
MMAE.
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